Aytu BioPharma, Inc.AYTU

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · aytubio.com

Aytu BioPharma, Inc. is a pharmaceutical company headquartered in Denver, Colorado, focused on commercializing prescription therapeutics for complex central nervous system (CNS) diseases. The company's portfolio targets major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD), including EXXUA™ (gepirone) extended-release tablets approved for MDD in adults. Formerly known as Aytu BioScience, Inc., the company changed its name in March 2021.

Key ratios

Operating cash flow growth

-89.0%TTM

FCF / Sales

-1.1%TTM

2025 -3.3%2024 -2.6%2023 -6.9%

Net margin

-39.0%TTM

2025 -20.4%2024 -24.3%2023 -23.1%

ROA

-0.2%TTM

2025 1.3%2024 0.3%2023 -2.4%

ROE

-109.2%TTM

2025 -60.8%2024 -37.3%2023 -18.1%

Revenue growth

2.0%TTM

2025 1.8%2024 -11.7%2023 -23.7%

Recent news

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 2026-06-01 · Newswire Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results 2026-05-13 · Investing News Network

Track AYTU in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer